MedGenome Secures $30M in Series C Funding
Summary
MedGenome, a Foster City, Calif.-based genomics research and diagnostics company, completed a $30m Series C financing.These efforts will enable American and European genomic and biopharmaceutical researchers to access MedGenome’s advanced research solutions and leverage the world’s most diverse genetic variant database, drawn from Indian population, for early drug discovery and target validation.Led by Sam Santhosh, Founder, Chairman and Global CEO, MedGenome is a genomics-driven research and diagnostics company which decodes genetic information contained in an individual’s genome.Its proprietary diagnostics tests, offered in India, include a liquid biopsy (OncoTrack) for monitoring cancer treatment, non-invasive prenatal screening test (NIPT) for pregnant women, carrier screening for couples planning for children, and whole exome sequencing for identification of rare mutations.MedGenome is also a founding member of GenomeAsia 100K initiative to sequence 100,000 Genomes in South, North and East Asia.